Clinical Trials

Multiple Myeloma

NCT04094961 2026-03-05

Ixazomib + Pomalidomide + Dexamethasone In MM

52 enrolled

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

39 enrolled

Multiple Myeloma

NCT01297764 2026-02-19

QUAD

17 enrolled

Multiple Myeloma

NCT06988488 2026-02-02

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT01665794 2025-12-22

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

25 enrolled

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

300 enrolled

Multiple Myeloma, Recurrence

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

49 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05392946 2025-10-29

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

49 enrolled

Multiple Myeloma

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

37 enrolled

Multiple Myeloma

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

87 enrolled 13 charts

Amyloidosis, Multiple Myeloma

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

53 enrolled

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

23 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02542657 2024-09-19

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

30 enrolled

Neoplasms, Plasma Cell

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

33 enrolled 26 charts

Chromosome 17 deletion, Multiple Myeloma

NCT02773030 2024-06-25

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

466 enrolled

Multiple Myeloma, Recurrence

NCT02119468 2024-03-15

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

32 enrolled 15 charts

Multiple Myeloma

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

45 enrolled

Multiple Myeloma, Recurrence

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

28 enrolled 10 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

136 enrolled

Multiple Myeloma

NCT01946152 2021-07-30

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

21 enrolled 14 charts

Multiple Myeloma

NCT02545907 2021-04-15

CATALYST

10 enrolled 14 charts

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT01155583 2020-11-16

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

45 enrolled 20 charts

Multiple Myeloma

NCT00966693 2020-11-04

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

77 enrolled 19 charts

Multiple Myeloma

NCT02477215 2020-10-22

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

38 enrolled 18 charts

Multiple Myeloma

NCT01212952 2020-04-17

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

50 enrolled 12 charts

Multiple Myeloma

NCT01049945 2020-02-11

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

70 enrolled 11 charts

Multiple Myeloma

NCT02289222 2019-11-05

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

48 enrolled 10 charts

Multiple Myeloma, Recurrence

NCT03856112 2019-03-26

Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma

Phase 1/2 Withdrawn

Multiple Myeloma

NCT00790842 2018-10-24

PrE1003

63 enrolled 14 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01355705 2018-09-18

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

14 enrolled 9 charts

Multiple Myeloma

NCT00849251 2017-09-08

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

31 enrolled 10 charts

Multiple Myeloma

NCT01432600 2017-05-23

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

80 enrolled 12 charts

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT02802163 2017-04-25

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Phase 1/2 Withdrawn

Multiple Myeloma

NCT02353572 2015-03-09

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

3 enrolled 5 charts